Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Trial of Selinexor, Cyclophosphamide and Prednisone vs Cyclophosphamide and Prednisone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

NCT06212596 is registered in ClinicalTrials.gov with University of Leeds as lead sponsor.

NCT NCT06212596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06212596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Trial of Selinexor, Cyclophosphamide and Prednisone vs Cyclophosphamide and Prednisone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients
Lead sponsor
University of Leeds
Phase
Phase 2
Overall status
Completed
Start date
July 16, 2018
Completion date
November 14, 2023
Enrollment
66 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma